[Experimental study on effect of Tongxinluo on nerve cell apoptosis after cerebral ischemia in middle cerebral arterial obstructive model rats].
OBJECTIVE
To explore the action mechanism of Tongxinluo Capsule (TXL) in protecting brain from ischemic damage.


METHODS
SD rats were divided into five groups randomly, the sham operation group, the model group, the MK-801 group, the large and low dosage TXL groups (TXLL and TXLS). After the middle cerebral arterial obstructive (MCAO) model was established, peritoneal injection of MK-801 0.5 mg/kg per day was given to the MK-801 group, and 1.0 g/(kg x d) and 0.5 g/(kg x d) of TXL powder was administered in twice via gastrogavage to the two TXL groups respectively. The nerve cell apoptosis rate, protein and mRNA expressions of Caspase-3, p53 and heat shock protein (HSP70) were observed using flow cytometry, Western blot and RT-PCR technique.


RESULTS
Both TXL and MK-801 could obviously lower the apoptosis rate in model rat (P < 0.05, P < 0.01), TXLL showed the optimal effect. Caspase-3, p53 protein and mRNA expression in the model group were obviously higher than those in the sham operated group. As compared with the model group, the expressions of Caspase-3 and p53 were lower and those of HSP70 and mRNA were higher in the two TXL and MK-801 groups (P < 0.05 or P < 0.01).


CONCLUSIONS
TXL displays it brain protective effect through reducing nerve cell apoptosis rate in MCAO model rats, the mechanism may be related to its actions in inhibiting apoptosis related factors Caspase-3 and p53, and promoting stress protecting factor HSP70.
Yuan
Guo-qiang
GQ
Yiling Medical Academy of Hebei, Shijiazhuang. yuanguoqiang7508@163.com
Wu
Yi-ling
YL
Jia
Zhen-hua
ZH
D000818:Animals; D017209:Apoptosis / Q000187:drug effects*; D001157:Arterial Occlusive Diseases / Q000209:etiology / Q000503:physiopathology*; D015153:Blotting, Western; D002545:Brain Ischemia / Q000150:complications; D002214:Capsules; D053148:Caspase 3 / Q000096:biosynthesis / Q000235:genetics; D002536:Cerebral Arteries / Q000473:pathology / Q000503:physiopathology; D004195:Disease Models, Animal; D016291:Dizocilpine Maleate / Q000627:therapeutic use; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D008297:Male; D009474:Neurons / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D020133:Reverse Transcriptase Polymerase Chain Reaction; D016159:Tumor Suppressor Protein p53 / Q000096:biosynthesis / Q000235:genetics
D002214:Capsules; D004365:Drugs, Chinese Herbal; D018696:Neuroprotective Agents; D012333:RNA, Messenger; D016159:Tumor Suppressor Protein p53; C513941:tongxinluo; D016291:Dizocilpine Maleate; D053148:Caspase 3